References
- Moret C, Charveron M, Finberg JP, Couziner J-P, Briley M. Biochemical profile of midalcipran, 1-phenyl-1-diethylaminocarbonyl-2-aminoethylcyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuro-pharmacology 1985;24: 1211–9
- Stenger A, Couzinier JP, Briley M. Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-aminocarbonyl-2-aminoethylcyclopropane (Z) hydrochloride, a new potential antidepressant. Psychopharmacology 1987;91: 147–53
- Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 1996;11(Suppl 4):9–14
- Lecrubier Y, Plétan Y, Solles A, Tournoux A, Magne V. Clinical efficacy of milnacipran: placebo-controlled trials. Int Clin Psychopharmacol 1996;11(Suppl 4):29–33
- Spencer CM, Wilde MI. Milnacipran. A review of its use in depression. Drugs 1998;56:405–27
- Rouillon F, Berdeaux G, Bisserbe JC, et al. Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. J Affect Disord 2000;58:171–80
- Rouillon F, Warner B, Pezous N, et al. Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. Milnacipran recurrence prevention study group. Int Clin Psychopharmacol 2000;15:133–40
- Kasper S, Plétan Y, Solles A, Tournoux A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 1996;11(Suppl 4):35–9
- Montgomery SA, Prost JF, Solles A, Briley M. Efficacy and tolerability of milnacipran: an overview. Int Clin Psycho-pharmacol 1996;11(Suppl 4):47–51
- Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline uptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12:99–108
- Lopez-Ibor J, Guelfi JD, Plétan Y, Tournoux A, Prost J-F. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996;11(Suppl 4):41–6
- Dardennes R, Berdeaux G, Lafuma A, Fagnani F. Comparison of the cost-effectiveness of milnacipran (a SNRI) with TCAs and SSRIs: a modelling approach. Eur Psychiatry 1999;14:152–62
- Tignol J, Pujol-Domenech J, Chartres JP, et al. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episodes. Acta Psychiat Scand 1998;97:157–65
- Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–9
- Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278–96
- Guelfi JD, Pull CB, Guelfi C, Ruschel S, Dreyfus JF. La C.H.E.S.S.: utilisation dans la pathologie anxieuse et dépression. Ann Med Psychol (Paris) 1983;14:257–77
- Van Amerongen AP, Ferrey G, Tournoux A. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. J. Affect Disord 2002;72:21–3
- Ferrier IN. Treatment of major depression: is improvement enough? J Clin Psychiatry 1999;60(Suppl 6):10–4